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Abstract
Anti-angiogenic therapies using biological molecules that neutral-
ize vascular endothelial growth factor-A (VEGF-A) have revolution-
ized treatment of retinal vascular diseases including age-related
macular degeneration (AMD). This study reports preclinical assess-
ment of a strategy to enhance anti-VEGF-A monotherapy efficacy
by targeting both VEGF-A and angiopoietin-2 (ANG-2), a factor
strongly upregulated in vitreous fluids of patients with retinal
vascular disease and exerting some of its activities in concert with
VEGF-A. Simultaneous VEGF-A and ANG-2 inhibition was found to
reduce vessel lesion number, permeability, retinal edema, and
neuron loss more effectively than either agent alone in a sponta-
neous choroidal neovascularization (CNV) model. We describe the
generation of a bispecific domain-exchanged (crossed) monoclonal
antibody (CrossMAb; RG7716) capable of binding, neutralizing, and
depleting VEGF-A and ANG-2. RG7716 showed greater efficacy than
anti-VEGF-A alone in a non-human primate laser-induced CNV
model after intravitreal delivery. Modification of RG7716’s FcRn
and FccR binding sites disabled the antibodies’ Fc-mediated
effector functions. This resulted in increased systemic, but not
ocular, clearance. These properties make RG7716 a potential next-
generation therapy for neovascular indications of the eye.
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Introduction
The retina is supplied with oxygen, nutrients, and waste exchanges
by two distinct vascular beds: the retinal and choroidal capillary
networks. Abnormal leakage and/or neovascularization from retinal
vessels are the hallmarks of diseases such as diabetic macular
edema (DME), diabetic retinopathy (DR), and retinal vein occlusion
(RVO) (Penn et al, 2008; Wang & Hartnett, 2016). Wet age-related
macular degeneration (wAMD) develops when new vessels grow
into the subretinal space from the underlying choroidal capillary
network underneath the outer retina (Campochiaro, 2013). Micro-
angiopathy, neovascularization, and vascular leakage from choroidal
and retinal capillaries are the most common causes of moderate and
severe vision loss in developed countries (WHO, 2014).
The importance of vascular endothelial growth factor (VEGF)-A
in pathological angiogenesis, particularly in oncology and eye
diseases, led to the development of several agents for clinical inter-
vention. Anti-VEGF-A-based therapies are now the standard of care
for a variety of solid tumor indications and ocular neovascular
diseases, such as wAMD, DME, and RVO. One way of enhancing the
efficacy of anti-VEGF-A-based therapies is adding the inhibition of
another soluble factor to the therapeutic reagent that is also
essential for angiogenesis (Jo et al, 2006).
1 Roche Pharma Research and Early Development, Roche Innovation Center München, Penzberg, Germany
2 Department of Ocular Biology and Therapeutics, UCL London, Institute of Ophthalmology, London, UK
3 Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland
4 Translational Pre-Clinical Model Platform, Singapore Eye Research Institute, The Academia, Singapore, Singapore
5 The Ophthalmology & Visual Sciences Academic Clinical Program, DUKE-NUS Graduate Medical School, Singapore, Singapore
6 Department of Ophthalmology, Goethe University, Frankfurt am Main, Germany
7 Department of Ophthalmology, Ruprecht Karls University, Heidelberg, Germany
8 Roche Pharma Research and Early Development, Roche Innovation Center Zürich, F. Hoffmann-La Roche Ltd, Zürich, Switzerland
*Corresponding author. Tel: +41 616874588; Fax: +41 616880382; E-mail: guido.hartmann@roche.com
†These authors contributed equally to this work
ª 2016 F. Hoffmann-La Roche Ltd. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 8 | No 11 | 2016 1265
The angiopoietins ANG-1 and ANG-2 are growth factors that
play a key role in vessel homeostasis, angiogenesis, and vascular
permeability. Both ligands interact with the Tie-2 transmembrane
receptor tyrosine kinase. Tie-2 is preferentially expressed on
endothelial cells and a subset of myeloid cells. Loss- and gain-of-
function experiments have demonstrated the critical contributions
of the angiopoietin/Tie-2 system in vascular development and
vascular diseases (Puri et al, 1995; Asahara et al, 1998; Augustin
et al, 2009). Tie-2 receptor-deficient mice die by embryonic day
10.5 as a result of vessel immaturity and incorrect vessel organi-
zation (Dumont et al, 1994; Sato et al, 1995). ANG-1-deficient
mice show a phenotype that is reminiscent of the Tie-2-deficient
phenotype (Suri et al, 1996), while transgenic overexpression of
ANG-2 mimics the phenotype of Tie-2- and ANG-1-deficient mice,
suggesting that ANG-1 and ANG-2 have opposing activities. Both
Tie-2 ligands bind to the receptor with similar affinity, whereas
only ANG-1 induces strong phosphorylation of the kinase domain
and subsequent signaling events. ANG-2 has been characterized
as a partial Tie-2 agonist that competitively inhibits ANG-1 signal-
ing (Maisonpierre et al, 1997; Saharinen et al, 2008). Structural
studies have identified an agonistic loop (P-domain) in ANG-1
that is capable of converting ANG-2 into a full agonist on
chimerization (Yu et al, 2013). ANG-2 also amplifies proapoptotic
signals in pericytes under stress from elevated glucose conditions
or proinflammatory cytokines like TNF-a (Cai et al, 2008; Park
et al, 2014). Overall data suggest that ANG-1 protects from
pathological angiogenesis and drives toward a quiescent, mature
vessel phenotype (Nambu et al, 2004; Hammes et al, 2011; Lee
et al, 2014), whereas ANG-2 promotes vascular leakage and
hypotensive, abnormal vessel structure (Ziegler et al, 2013).
Interaction of the angiopoietins with the VEGF-A pathway has
been studied in ocular setting using double transgenic mice co-
expressing ANG-1 and VEGF-A. ANG-1 expression, when initiated
simultaneously with VEGF-A, suppressed VEGF-A-induced neovas-
cularization and prevented retinal detachment (Nambu et al, 2005).
Although ANG-1 effectively blocked the initiation and progression
of VEGF-A-induced neovascularization, no impact on previously
established lesions was observed (Nambu et al, 2005). Conversely,
co-expression of ANG-2 with VEGF-A in the developing retina and
in ischemic retina models showed accelerated neovascularization
compared to VEGF-A expression alone (Oshima et al, 2004, 2005).
Further pathophysiological significance arises from reports of
elevated levels of VEGF-A and ANG-2 in vitreous samples from
diabetic patients undergoing vitrectomy, which correlate with each
other and with disease severity (Watanabe et al, 2005; Loukovaara
et al, 2013). Therefore, VEGF-A and ANG-2 appear strongly linked
to normal vascular development, but also to pathological neovascu-
larization and vascular permeability, which are the hallmarks of
ocular neovascular disease.
Several bispecific antibodies are currently in clinical develop-
ment, including an anti-VEGF-A/ANG-2 bispecific antibody targeting
neovascularization in tumors (Kienast et al, 2013). The aim of this
study was to explore the potential of dual VEGF-A and ANG-2
inhibition in the management of retinal vascular diseases. We tested
monotherapy and dual inhibition of VEGF-A/ANG-2 using a species
crossreactive CrossMAb in the spontaneous model of CNV in
JR5558 mice. We then developed a human bispecific CrossMAb
(RG7716), which binds and neutralizes human VEGF-A and ANG-2
with high potency and tested it in the laser-induced model of CNV
in non-human primates. Our data suggest that dual inhibition of
these angiogenic signaling circuits improves outcomes in preclinical
models of ocular neovascular disease.
Results
ANG-2 levels are elevated in human retinal vascular diseases
To investigate whether ANG-2 is a suitable pharmacological target for
human retinal vascular diseases, we measured the levels of ANG-1
and ANG-2 in the vitreous of patients newly diagnosed with wet
AMD, DR, proliferative DR, or RVO in comparison with macular hole
as controls, as described in Koss et al (2011). In human vitreous
samples, ANG-1 levels were weakly elevated in RVO (71.1 up to
107 pg/ml) and decreased in proliferative DR (down to 36.3 pg/ml)
compared to controls (Fig 1A). However, levels of ANG-2 were signifi-
cantly elevated in all four retinal vascular diseases investigated
compared to controls (Fig 1B). From control levels of 68.4 pg/ml,
ANG-2 increased to 139 pg/ml in wet AMD, to 302 pg/ml in DR, to
1,140 pg/ml in RVO, and to 1,625 pg/ml in proliferative DR.
▸Figure 1. Vitreous concentrations of angiopoietins in patients newly diagnosed with retinal diseases and cell model of barrier breakdown testing theinteraction of VEGF-A and angiopoietins.
A, B Box plots of vitreal ANG-1 (A) and ANG-2 (B) levels from newly diagnosed patients with wAMD, DR, proliferative DR and RVO compared to controls (macular hole).
The interquartile range of the data is indicated by the box. A nonparametric Kruskal–Wallis analysis followed by Dunn’s method for multiple comparisons was used
to show significant differences of the groups to control which are indicated by asterisks. ANG-1 levels did not differ significantly, but ANG-2 levels were significantly
different: control vs. AMD (*, P = 0.0451), vs. DR (****, P < 0.0001), pDR (****, P < 0.0001), and RVO (****, P < 0.0001).
C Schematic of cellular experiments to measure transendothelial resistance in human endothelial cells using transwell filters and CellZscope technology.
D 24-h concentration of ANG-2 in supernatants of the basal side of the culture stimulated with 5 ng/ml of VEGF-A, 200 ng/ml of ANG-1, or the combination. Error
bars show SEM with one-sided ANOVA (P < 0.0001) and Tukey’s multiple t-test for five independent experiments indicating significance for control vs. VEGF-A
(**, P = 0.0028); VEGF-A vs. ANG-1 (****, P < 0.0001); ANG-1 vs. VEGF-A and ANG1 (**, P = 0.0061); VEGF-A vs. VEGF-A and ANG-1 (ns, P = 0.0625).
E Human endothelial cells plated on filters were assessed for endothelial barrier function over time after the addition of 5 ng/ml VEGF-A alone or in combination
with 200 ng/ml ANG-1 or 10 lg/ml anti-ANG-2 or all three test items. The final time point was used for statistical analysis. Error bars show SEM with one-sided
ANOVA (P < 0.0001) and Tukey’s multiple t-test for three independent experiments indicating significance of VEGF-A vs. untreated (****, P < 0.0001); vs. VEGF-A
and ANG-1 and anti-ANG-2 (***, P = 0.0004); vs. VEGF-A and anti-ANG-2 (*, P = 0.038); vs. VEGF-A and ANG-1 (*, P = 0.040). Furthermore, VEGF-A and anti-ANG-2
and ANG-1 are significantly different vs. VEGF-A and ANG-1 (*, P = 0.0451); vs. VEGF-A and anti-ANG-2 (*, P = 0.0474); vs. untreated (*, P = 0.0492). Finally
untreated is significantly different vs. VEGF-A and ANG-1 (***, P = 0.0009) and VEGF-A and anti-ANG-2 (***, P = 0.0008).
Data information: ANOVA, analysis of variance; SEM, standard error of the mean; ANG-2, angiopoietin-2; DR, diabetic retinopathy; RVO, retinal vein occlusion; wAMD, wet
age-related macular degeneration; pDR, proliferative diabetic retinopathy; vs., versus.
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Interplay of VEGF-A and angiopoietins in a model of endothelial
barrier breakdown
We then investigated the interplay between VEGF-A and the
angiopoietins in a barrier breakdown model in human primary
endothelial cells, in order to better understand some of the cellular
aspects leading to hyperpermeability in patients (Fig 1C–E). Human
endothelial cells in culture secrete large amounts of ANG-2 into the
supernatant. VEGF-A increases the amount of ANG-2 even further,
whereas ANG-1 reduces the secretion of ANG-2. Combined exposure
of endothelial cells to VEGF-A and ANG-1 showed a trend to reduce
ANG-2 production induced by VEGF-A (Fig 1D). Endothelial barrier
breakdown is a key event in retinal eye disease, with edema being a
major driver of pathology in the retina. VEGF-A is a known inducer
of endothelial barrier breakdown and, indeed, we measured
progressive loss of endothelial barrier function over time in our
model. We then tested whether ANG-2 present in the culture contri-
butes to VEGF-A-induced barrier breakdown. When adding anti-
ANG-2 together with VEGF-A, barrier breakdown was reduced. This
suggests that VEGF-A, at least partly, signals via ANG-2 to trigger
endothelial barrier breakdown. The addition of ANG-1 also reduced
VEGF-A-induced barrier breakdown, demonstrating an improved
BA
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endothelial monolayer integrity function of ANG-1. Combined addi-
tion of anti-ANG-2 and ANG-1 reduced the VEGF-A-induced barrier
breakdown even further (Fig 1E). The dynamic nature of VEGF-A-
induced barrier breakdown was demonstrated when a bispecific
anti-VEGF-A/ANG-2 was added 18 h after the addition of VEGF-A.
TEER values reverted back to values before the addition of VEGF-A
to the culture (Appendix Fig S1). The results confirm the concept of
VEGF-A and ANG-2 being drivers of endothelial barrier breakdown,
while ANG-1 counteracts these activities and promotes normal
vessel integrity.
Monotherapy of anti-VEGF-A vs. combination therapy of
anti-VEGF-A and anti-ANG-2 in rodent models of
ocular neoangiogenesis
We then turned to a model of spontaneous CNV (sCNV) in the
JR5558 mouse strain to further probe the potential for anti-
VEGF-A/ANG-2 combination therapy. The sCNV model develops
leaky, neovascular tufts arising from the choriocapillaries, which
resemble human choroidal lesions. The pathological consequences
of these leaky neovessels distorting the retinal architecture can be
seen by increased neuroretinal cell death and loss of retinal func-
tionality observed using electroretinography. The model also shows
increased expression of VEGF mRNA in the RPE/choroid and retina
when compared to wild-type mice. Inhibition of VEGF receptor-2
using a blocking antibody reduced the severity of neovasculariza-
tion, making this a suitable model to test for combination therapies
that enhance the efficacy of anti-VEGFs (Nagai et al, 2014). We first
probed for ANG-2 expression in the model and found that ANG-2
mRNA was elevated in the choroid/RPE, but not retina, of JR5558
mice compared to wild-type mice starting at day 27 and increasing
further as measured at days 50 and 62 (Fig 2A and B).
Next, we directly tested the concept of combined inhibition of
VEGF-A and ANG-2 being more efficacious than VEGF-A inhibition
alone in preventing neovascularization and its associated endo-
thelial dysfunction. In all rodent experiments, we used the rodent
crossreactive B20-4.1 Fab arm (Liang et al, 2006) and the anti-
ANG2-LC10 antibody generated as CrossMAbs or IgGs, as indicated
(Schaefer et al, 2011). Since neovascular tufts arise from the chorio-
capillaris between postnatal day (D)10 and D15 and lesion numbers
peak at approximately D30 in this model (Nagai et al, 2014), admin-
istration of antibodies was initiated at D14 and D19 by intraperi-
toneal (IP) injection (termed early intervention mode; Fig 2C). At
D26, fluorescein angiography (FA) was performed, and lesion
number and size were evaluated. Anti-VEGF-A and anti-ANG-2 were
tested at 5 mg/kg while the anti-VEGF-A/ANG-2 antibody was
tested in a dose–response with 10, 5, and 3 mg/kg. A normal IgG1
can bind two molecules of VEGF-A or ANG-2 (one per Fab arm), but
an anti-VEGF-A/ANG-2 CrossMAb only one of each ligand. There-
fore, the 10 mg/kg high dose of the anti-VEGF-A/ANG-2 CrossMAb
has an equal molar concentration of binding sites as 5 mg/kg of
standard IgG1 (anti-VEGF-A, anti-ANG-2, or IgG control). Anti-
VEGF-A reduced the number and lesion area significantly compared
to IgG control, while anti-ANG-2 alone showed a trend toward
reduction. The highest doses of anti-VEGF-A/ANG-2 CrossMAb
significantly reduced the number and size of lesions compared to
IgG control and anti-VEGF-A or anti-ANG-2 monotherapy alone
(Fig 2D–K).
Choroidal neovascularization progressively damages the retina,
so later time points were investigated in the mouse model to more
closely reflect the clinical situation in which a patient presents with
established disease. In the late intervention model, antibody is given
when a considerable number of lesions with parainflammation and
neuronal cell death are already established (Nagai et al, 2014). Anti-
body was given once a week for 2 weeks from D47 onwards, with
examination at D60. In these experiments, we compared both anti-
VEGF-A and anti-ANG-2 alone to bispecific VEGF-A/ANG-2
CrossMAb antibody (CrossMAb and IgG control at 3 mg/kg dose,
▸Figure 2. Inhibition of vessel leakiness and lesion number by combined inhibition of VEGF-A and ANG-2 in themodel of sCNV in JR5558mice using fluorescenceangiography.
A, B Real-time qPCR analysis of ANG-2 levels in retina and RPE/choroid complexes of JR5558 and C57BL/6J (C57) mice. (A) Relative expression levels of ANG-2 were
significantly increased in the RPE/choroid complexes of JR5558 mice in comparison with C57, at 50 and 62 days old (*, P = 0.022 at D50 and *, P = 0.042 at D62).
(B) By contrast, retina levels of ANG-2 were not significantly different between C57 and JR5558 mice, indicating neovascularization is driven locally by ANG-2.
Asterisk (*) denotes statistical significance of JR5558 mice compared to wild-type C57BL/6 using unpaired t-test for each time point analyzed separately.
C Schematic presentation of experimental design. Mice received IP injections of CrossMAb anti-VEGF-A/ANG-2 (species crossreactive, B20-4.1 and LC10), anti-ANG-2
(LC10), an anti-VEGF-A IgG1 (B20-4.1), or IgG control at postnatal D14 and D19 followed by fluorescence angiography at D26 (early intervention), results
demonstrated in (D–K). Alternatively, mice received antibody at postnatal D47 and D55 followed by fluorescence angiography at D60 (late intervention), results
demonstrated in (L) and (M).
D–I Representative examples of fluorescence angiograms of IgG control (D), anti-VEGF-A (E), anti-ANG-2 (F) (all at 5 mg/kg), and three doses of anti-VEGF-A/ANG-2
(G, H, and I) (at 3, 5, and 10 mg/kg).
J, K Bar graph of numbers of spontaneously occurring lesions (J) and area by fluorescence angiography (K) after two weekly doses of antibody (antibodies at 5 mg/kg IP
and anti-VEGF-A/ANG-2 at 10 [high], 5 [mid], and 3 [low] mg/kg IP) followed by analysis a week later in the early intervention model.
L, M Bar graph of numbers of spontaneously occurring lesions (L) and area by fluorescence angiography (M) after two weekly doses of antibody (3 mg/kg IP) followed by
analysis a week later in the late intervention model.
Data information: SEM is shown as error bars with n = 4 (A, B) or n = 8 (J–M) animals per group and significance indicated by * using ANOVA (J, K: P < 0.0001;
L: P < 0.0018; M: P < 0.031 followed by Tukey’s multiple t-test in J–M). In (J), IgG control is significant against anti-VEGF-A (****, P < 0.0001), anti-ANG-2 (**, P = 0.0069),
anti-VEGF-A/ANG-2 low (*, P = 0.0194), mid and high (****, P < 0.0001). Furthermore, anti-VEGF-A/ANG-2 high is significant against anti-VEGF-A (*, P = 0.0428), anti-
ANG-2 (****, P < 0.0001), and anti-VEGF-A/ANG-2 low (****, P < 0.0001). Finally, anti-ANG-2 is significantly different from anti-VEGF-A/ANG-2 mid (**, P < 0.0041). In (K),
IgG control is significant against anti-VEGF-A (***, P = 0.0003) and anti-VEGF-A/ANG-2 mid and high (both ****, P < 0.0001). Furthermore, anti-VEGF-A/ANG-2 high is
significantly different from anti-VEGF-A (**, P = 0.0037), anti-ANG-2 (****, P < 0.0001), and anti-VEGF-A/ANG-2 low (***, P = 0.0001). Finally, anti-ANG-2 is significantly
different from anti-VEGF-A/ANG-2 mid (**, P < 0.0022) and anti-VEGF-A/ANG-2 low against mid (*, P = 0.022). In (L), IgG control is significantly different from anti-ANG-2
(*, P = 0.023) and anti-VEGF-A/ANG-2 (*, P = 0.014). Vehicle is different from anti-ANG-2 (*, P = 0.024) and anti-VEGF-A/ANG-2 (*, P = 0.016). In (M), IgG control is
significantly different from anti-ANG-2 (*, P = 0.044) and anti-VEGF-A/ANG-2 (*, P = 0.049). D, day; IP, intraperitoneal; sCNV, spontaneous choroidal neovascularization.
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VEGF-A and ANG-2 antibodies at 1.5 mg/kg). The reduction in the
number of lesions with this late intervention regimen was less
compared to early intervention when antibodies were administered
while lesions were developing (Fig 2L). However, despite a small
reduction in lesion number by anti-ANG-2 and anti-VEGF-A/ANG-2,
the reduction did reach statistical significance compared to IgG
control and vehicle (Fig 2L). In contrast to lesion number,
pronounced reductions in the area of lesions were apparent for anti-
VEGF-A/ANG-2 CrossMAb compared to IgG control and a trend
compared to vehicle under these experimental conditions, as for
anti-ANG-2, whereas anti-VEGF-A did not have a statistically signifi-
cant impact (Fig 2M).
Leaky neovessels in the JR5558 model result in the accumulation
of fluid in the retina, which can be monitored noninvasively using
optical coherence tomography (OCT). Topographical maps of OCT
volumes demonstrated areas of subretinal elevation delineating
fluid-filled regions. These areas correlated with regions of leakiness
demonstrated by FA (Fig 3B). Image analysis of these areas revealed
a reduction in volume of subretinal edema in mice treated with 1, 5,
and 10 mg/kg bispecific anti-VEGF-A/ANG-2. No significant reduction
was seen with anti-ANG-2 or VEGF-A alone at 5 mg/kg. (Fig 3A and B).
We then tested the concept of combined inhibition of VEGF-A
and ANG-2 in pathological neovascularization in a second mouse
model, namely oxygen-induced retinopathy (Appendix Fig S2A). It
is used as a model mimicking retinal neovascularization in retinopa-
thy of prematurity (ROP) and other vasculopathologies. The VEGF-A
dependence of this model has been demonstrated (Aguilar et al,
2008; Hartnett et al, 2008; Barnett et al, 2010). Indeed, anti-VEGF-A
treatment at 10 mg/kg IP at D14 increased the avascular area in the
center of the retina as anticipated. Dual inhibition with bispecific
anti-VEGF-A/ANG-2 increased the avascular area significantly
further, beyond IgG control and anti-VEGF-A (Appendix Fig S2B).
Significant reduction in neovascular tufts at the periphery was only
achieved by the bispecific anti-VEGF-A/ANG-2 treatment under
these conditions (Appendix Fig S2C).
Combined inhibition of VEGF-A and ANG-2 reduces
retinal inflammation
Inflammation around the CNV lesion is an important contributory
factor in the spontaneous CNV model, and ANG-2 has been
described as an enhancer of inflammatory signals in the context of
endothelial dysfunction (Fiedler et al, 2006; Benest et al, 2013).
Confocal microscopy was used to assess the number of IBA-1-positive
macrophages within and around the CNV lesion that reside proxi-
mal to the isolectin-B4-positive endothelial cells around the CNV
lesions (Fig 4A–G). Administration of bispecific anti-VEGF-A/ANG-2
at 10, 5, and 3 mg/kg strongly reduced the amount of IBA-1-positive
macrophages in the retina and around the lesions compared to anti-
VEGF-A or anti-ANG-2 treatment alone (Fig 4A).
To differentiate whether the reduction in lesion-associated
macrophages is a direct anti-inflammatory effect or a consequence
of reduced endothelial dysfunction and neovascularization, we
tested the antibodies in a proinflammatory mediator challenge
model for retinal leukocyte infiltration. Mice were challenged
systemically with lipopolysaccharide (LPS). Retinal cross sections
and aqueous fluids were then analyzed for leukocyte infiltration.
Antibody was given IP at 10 mg/kg 24 h before the LPS challenge.
Dual inhibition of VEGF-A and ANG-2 using a CrossMAb significantly
reduced the number of leukocytes in the retina and the aqueous
compartment (Appendix Fig S3A–C). Administration of anti-VEGF-A
and anti-ANG-2 as mixed IgG combinations, rather than bispecific
CrossMAb, gave similar results, and demonstrates that the
CrossMAb format does not affect the neutralization function of the
ligand-binding arm. No single treatment (anti-VEGF-A or anti-
ANG2) was as effective as the combination treatments
(Appendix Fig S3A–C).
Combined inhibition of VEGF-A and ANG-2 decreases retinal
neuroglial apoptosis and increases visual function in
spontaneous CNV model
Invasion of choroid capillaries into the RPE and subretinal spaces,
and the associated inflammatory cells, eventually causes disruption
of retinal architecture, leading to photoreceptor cell death and
dysfunction. We investigated the number of TUNEL-positive cells in
the outer retina (photoreceptor nuclei) in the late intervention regi-
men (Fig 5A–G). Monotreatments (anti-VEGF-A, anti-ANG-2 [both
at 5 mg/kg]) and the lowest dose (1 mg/kg) of bispecific VEGF-A/
ANG-2 antibody led to a mild reduction in TUNEL-positive cells in
the outer retina. In contrast, 5 and 10 mg/kg of the bispecific anti-
VEGF-A/ANG-2 significantly reduced numbers by up to 66%
compared to controls.
Using electroretinography (ERG), we also assessed neuroretinal
function in response to large-field flash stimuli under both scotopic
and photopic conditions. A trend toward an increase in photopic
B-wave amplitude and reduced latency was observed in animals
administered anti-VEGF-A or anti-ANG-2; however, only anti-VEGF-
A/ANG-2 had a significant effect compared to the IgG control, under
both scotopic and photopic conditions (Fig 5H and I).
Overall, the data indicated that simultaneous inhibition of
VEGF-A and ANG-2 efficiently inhibited CNV lesion number and
▸Figure 3. Reduction in edema by dual VEGF-A and ANG-2 inhibition in late interference model in the retina of JR5558 mice at D60 as revealed by OCT.A Bar graph showing the relative change in OCT-measured volume between the outer nuclear layer and the RPE layer following intervention with test item.
Anti-VEGF-A and anti-ANG-2 were given at 5 mg/kg and anti-VEGF-A/ANG-2 at 1, 5, and 10 mg/kg (low, mid, and high dose).
B Representative OCT images converted to heat maps with the scaling grade given on the right of the figure delineating fluid-filled areas of the retina. Baseline (D46)
and 14-day treatments of IgG control, anti-VEGF-A, anti-ANG-2, and bispecific anti-VEGF-A/ANG-2 at the end of the experiment (D60) are shown. For the region of
interest, the corresponding FA image at D60 is also shown as comparator.
Data information: SEM is shown as error bars with n = 6 animals per group; significance is shown by * using one-sided ANOVA (P = 0.0048) followed by Tukey’s multiple
t-test. Significant changes are shown with anti-VEGF-A/ANG-2 high vs. anti-ANG-2 (**, P = 0.0069) and IgG control (*, P = 0.018). In addition, the comparison of anti-
VEGF-A vs. anti-VEGF-A/ANG-2 (high) is approaching significance (ns, P = 0.072). FA, fluorescein angiography; OCT, optical coherence tomography; RPE, retinal pigment
epithelium; vs., versus.
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Figure 4. Dual inhibition of VEGF-A and ANG-2 reduced the number of IBA-1+ macrophages in the model of sCNV in JR5558 mice.
A Bar graph of number of IBA-1+ cells in the retina of mice treated with IgG control, anti-VEGF-A, anti-ANG-2 (all 5 mg/kg IP), or bispecific anti-VEGF-A/ANG-2 (at 10,
5, and 3 mg/kg) in the late interference model at D60. Error bars show SEM with n = 6 animals per group. All significant differences are shown by * after one-sided
ANOVA (P < 0.0008) and Tukey’s multiple t-test. IgG control is significantly different vs. anti-VEGF-A/ANG-2 low (*, P < 0.0134), mid (**, P < 0.0078), and high (**,
P < 0.0042); furthermore, anti-ANG-2 is significantly different vs. anti-VEGF-A/ANG-2 mid (*, P < 0.0353).
B–G (B) IgG control, (C) anti-VEGF-A, (D) anti-ANG-2, (E–G) anti-VEGF-A/ANG-2 low, mid, and high: representative micrographs of whole-mount eyecup preparations
stained with isolectin-B4 positive (green) to stain vessels and anti-IBA1 (red) to stain for macrophages show a decrease in both absolute numbers and clustering of
subretinal IBA-1-expressing cells associated with neovascular complexes in anti-VEGF-A/ANG-2 treatment groups. Scale bar, 200 lm.
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area, retinal edema, and inflammation, plus promoted the survival
and functionality of the neuroretina, and thus could be a promising
strategy for the treatment of patients with ocular neovascular
disease.
Generation and characterization of a human CrossMAb antibody
targeting VEGF-A and ANG-2 with a modified Fc region optimized
for use in ophthalmology
High-affinity binding to VEGF-A and ANG-2 but no binding to ANG-1
To produce a molecule suitable for clinical development, we
generated the bispecific CrossMAb RG7716 based on the frame-
work of a 150-kDa human IgG1 (Schaefer et al, 2011). RG7716
comprises two different heavy chains and two different light
chains. One ligand-binding arm binds VEGF-A and the other binds
ANG-2 (Fig 6A). The affinity of the ligand binding of RG7716 was
determined using isothermal titration calorimetry (ITC), which
offers the advantage of affinity measurements in solution without
the strong influence of avidity. RG7716 bound human VEGF-A165
and VEGF-A121 with KD values of 3 nM, which was comparable to
the KD of ranibizumab (Fig 6B). Angiopoietins are oligomeric
proteins, which are difficult to use in kinetic studies. We therefore
used the angiopoietin receptor-binding domains (RBDs) as a Fc
fusion protein (Barton et al, 2006). RG7716 bound human ANG-2
RBD-Fc fusion protein with a KD value of 22 nM, whereas no
binding of human ANG-1 RBD-Fc fusion protein was detected
(Fig 6B). To confirm that RG7716 has no impact on ANG-1 signal-
ing, we compared LC10 (ANG-2 binding part in RG7716) to LC08,
a dual ANG-1/ANG-2 binding antibody, in ANG-1-mediated
endothelial survival assays using 120 ng/ml ANG-1 as a stimulus.
We tested concentrations of the antibodies up to 100 lg/ml and
observed a clear dose-dependent inhibition using the dual binding
antibody LC08; however, LC10 did not inhibit ANG-1-mediated
endothelial survival at any doses tested (Fig 6C). Independent and
simultaneous binding of both ANG-2 and VEGF-A by RG7716 was
demonstrated in surface plasmon resonance (SPR) experiments
(Fig 6D).
Optimization of RG7716 for retinal indications by engineering of
the Fc region
To optimize RG7716 for ophthalmological use, the Fc region was
engineered to abolish binding interactions with all FccR and FcRn
(Fig 7A–E, Table 1). Exchange of amino acids required for the
FccR interactions should eradicate effector functions including
antibody-dependent cytotoxicity (ADCC), antibody-dependent cell
phagocytosis (ADCP), and complement-dependent cytotoxicity
(CDC). Eliminating the FcRn binding site should reduce the
systemic half-life compared to wild-type IgG (due to the lack of
IgG recycling). The individual point mutations are listed in
Table 2. To demonstrate loss of binding of RG7716 to the appro-
priate human Fc receptors, FccRIa, FccRIIa, FccRIIIa, and FcRn
proteins were immobilized on a SPR affinity chip. No binding of
RG7716 to Fc receptors was detected, in contrast to the appropri-
ate wild-type and control anti-VEGF-A/ANG-2 antibodies (Fig 7A–
E). The mode of action of RG7716 is based on ligand binding and
neutralization; hence, the effector function of RG7716 is not
needed. There are reports that antibodies with two VEGF-A-
binding domains are capable of activating platelets in the presence
of proteoglycans, resulting in degranulation and thrombosis
in vivo (Meyer et al, 2009; Julien et al, 2014). We therefore tested
whether RG7716 has a similar potential to activate platelets.
Freshly isolated human platelets were activated in the presence of
complexes of heparin, VEGF-A, and RG7716 or anti-VEGF-A.
Although an anti-VEGF-A antibody with two antigen-binding
sites was capable of activating platelets, no effect was seen with
RG7716 (Fig 8A). The effect of eliminating the FcRn binding site
in RG7716 was tested in a comparative pharmacokinetic study in
non-human primates. We observed faster systemic clearance and
lower systemic exposure of RG7716 compared to anti-VEGF/
ANG-2-FccR (CrossMAb with intact FcRn binding) after single
intravitreal administration in cynomolgus monkeys (Macaca
fascicularis); while systemic concentrations were reduced, the
concentration of both drugs in aqueous humor was similar
(Fig 8B and C). In vitreous humor, concentrations were
measured only for RG7716. The concentrations in the vitreous
▸Figure 5. Dual inhibition of VEGF-A and ANG-2 reduced the number of TUNEL-positive cells and improved visual functionality, as revealed by ERG, in amodel ofsCNV in JR5558 mice.
A Bar graph of TUNEL-positive cells in the retina of mice treated with 5 mg/kg anti-VEGF-A, anti-ANG-2, and 3, 5, and 10 mg/kg anti-VEGF-A/ANG-2. Error bars show
SEM with n = 6 animals per group and * denotes all significant changes after one-sided ANOVA (P = 0.0041) and Tukey’s multiple t-test. IgG control is significantly
different from anti-VEGF-A/ANG-2 mid (**, P = 0.0077) and high (**, P = 0.0028).
B–G (B) IgG control, (C) anti-VEGF-A, (D) anti-ANG-2, (E–G) anti-VEGF-A/ANG-2 low, mid, and high: representative micrographs of whole-mount retinae preparations
display the reduction in TUNEL-positive photoreceptor cells (green) clustered around focal neovascular lesions in anti-VEGF-A/ANG-2 (E–G) and, to a lesser extent,
anti-VEGF-A-treated (C) and anti-ANG-2-treated (D) groups compared with IgG-treated controls (B) (scale bar, 200 lm).
H ERG was used to assess retinal function in response to large-field flash stimuli under both scotopic and photopic conditions. Representative photopic (light-
adapted) and scotopic (dark-adapted) flash response series show increased amplitude and reduced latency after treatment with bispecific anti-VEGF-A/ANG-2
compared with IgG control (both 3 mg/kg). ERG shows reduced depression of B-wave responses in JR5558 mice treated with anti-VEGF-A/ANG-2 compared to IgG
control.
I Maximum photopic ERG amplitude was increased using anti-VEGF-A/ANG-2 compared to single anti-VEGF-A or anti-ANG-2 treatments (all at 3 mg/kg). There was
a significant increase in amplitude at stimuli > 2 log (cd*s/m2) between the bispecific anti-VEGF-A/ANG-2 and IgG control group under scoptopic and photopic
conditions. Asterisk (*) denotes significance after ANOVA and Dunnett’s multiple t-test compared to IgG control compared for each stimuli separately; error bars
show SEM with n = 8 animals per group. Under photopic conditions, anti-VEGF-A/ANG-2 reached significance at 2.58 and 2.30 cd*s/m2 with *, P = 0.0498 and
*, P = 0.0479, respectively. Under scotopic conditions, all stimuli reached significance for anti-VEGF-A/ANG-2 at 2.3 cd*s/m2 (*, P = 0.0498); 1.93 cd*s/m2
(**, P = 0.0035); 1.63 and 1.33 cd*s/m2 (****, P < 0.0001); 1.03 cd*s/m2 (***, P = 0.0002); 0.73 cd*s/m2, (**, P = 0.004); 0.43 cd*s/m2, (**, P = 0.0024);
0.13 cd*s/m2 (**, P = 0.0024) and 0.18 cd*s/m2 (**, P = 0.0031). In addition, anti-ANG-2 treatment reached significance at 0.13 cd*s/m2 (+P = 0.011) and
0.18 cd*s/m2 (+P = 0.005), respectively.
Data information: ERG, electroretinogram; sCNV spontaneous choroidal neovascularization.
◀
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Figure 6. Structural characteristics and functional binding properties of CrossMAb RG7716.
A Structural presentation of CrossMAb RG7716 with substituted amino acids highlighted and colored. Amino acids corresponding to individual point mutations
ensuring correct and efficient heavy chain heterodimerization (“knobs-into-holes” [green] and additional disulfide bridge [yellow]), abolishing Fc receptor
functionality (Fcc receptors I, II, and III, [pink] and FcRn [blue]) are highlighted.
B Summary table of experimental binding affinities of the parental components targeting VEGF-A (ranibizumab) and ANG-2 (LC10) as well as of RG7716 measured by
isothermal titration calorimetry. RG7716 binds VEGF-A121 and VEGF-A165 with an affinity comparable to ranibizumab (3.3 vs. 3.1 nM). ANG-2 binding of RG7716 is
slightly decreased to 22 nM compared to a-ANG-2 IgG1 (LC10) with 4.1 nM. No binding to ANG-1 was detectable for RG7716 or a-ANG-2 IgG1 (LC10).
C Inhibition of ANG-1-induced endothelial cell survival was tested in the presence of increasing concentrations of LC10 (anti-ANG-2 IgG, ANG-2 binding part in RG7716)
and LC08 (ANG-1 and ANG-2 binding antibody). An average of three independent experiments is shown with SEM.
D The ability of RG7716 to bind to ANG-2 and VEGF-A simultaneously and independent is demonstrated by a surface plasmon resonance experiment. RG7716 is
captured via an anti-Fc antibody on the chip surface. The green curve depicts the experiment with ANG-2 in the first and VEGF-A in the second binding event. The
red curve shows the binding events in the other sequence.
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paralleled those in the aqueous over time, with the area under
the curve being approximately four times higher for the vitreous.
Flip-flop pharmacokinetics was observed for RG7716, with a
strong correlation between exposure in vitreous humor, aqueous
humor, and systemic circulation. These properties of RG7716
with good ocular, but low systemic, exposure were also con-
firmed in the following laser CNV study in non-human primates
(Appendix Fig S4A and B).
A B
C D
E
Figure 7. Binding of CrossMAbs with modification of the Fc part to FccRI, II, and III, as well as to FcRn in SPR interaction assays.
A–D Time-dependent binding of RG7716 is shown in blue, anti-VEGF-A/ANG-2 without modification of the Fc part in red (wild-type), anti-VEGF-A/ANG-2 with
modification of the FcRn binding site only in green (FcRn), and anti-VEGF-A/ANG-2 with modification of the FccR binding in pink (FccR). Panel (A) shows SPR
binding profile over time to immobilized FccRI, (B) to immobilized FccRII, (C) to immobilized FccRIII, and (D) to immobilized FcRn. SPR, surface plasmon resonance.
E Summary data table of binding data for RG7716 in comparison with anti-VEGF-A/ANG-2 CrossMAbs without modifications in the Fc part.
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Direct comparison of RG7716 to ranibizumab in the
laser-induced CNV model in non-human primates
Increased efficacy of RG7716 on reducing choroidal neovascularization
The laser-induced CNV model in non-human primates was chosen to
compare the efficacy of RG7716 to the anti-VEGF-A Fab fragment
ranibizumab, a US Food and Drug Administration (FDA)-approved
therapy for wAMD since 2006. In the experimental setup, the anti-
bodies were delivered by intravitreal injection, as done in the clinical
setting. The model offers the advantage of the similarities in the
cynomolgus monkey and human eyes, and circumvents the weak
inhibitory activity of ranibizumab against rodent VEGF-A. Lesions
were allowed to develop for 14 days following the initial laser injury.
A baseline fluorescein angiogram was taken from each eye at D14 to
determine the degree of vessel leakiness prior to antibody adminis-
tration. Lesions were blind-scored on a scale of 1–4, with 4 represent-
ing bright hyperfluorescence with late leakage beyond the laser spot,
3 representing hyperfluorescence with late leak only, 2 representing
hyperfluorescence only with no leakage, and 1 representing no
hyperfluorescence or leakiness. The average score per eye over all
groups was 3.45 at D14. Antibodies were delivered by intravitreal
injection on D15, 1 day after the baseline fluorescein angiogram
(Fig 9A). Antibody was injected at equal molar concentration of anti-
VEGF-A binding sites with 90 lg of 150-kDa RG7716 being equal to
30 lg of 50-kDa anti-VEGF-A Fab fragment (ranibizumab). A lower
dose of RG7716 (30 lg), anti-ANG-2 (90 lg), and an isotype control
(90 lg) was also tested. At D28, a second fluorescein angiogram
determined the change in vessel leakiness from baseline (at D14).
Lesions from control IgG antibody-treated eyes remained leaky and
showed no change in the degree of vessel leakiness from baseline.
All other antibodies reduced the degree of severity compared to
controls. Ranibizumab reduced the severity score by 0.85 and anti-
ANG-2 by 0.57. The 30 lg dose of RG7716 reduced the score by 0.67
and the 90 lg dose by 1.35. The equimolar dose of VEGF-A binding
sites for RG7716 (90 lg) was significantly better than anti-VEGF-A
(ranibizumab) in reducing vessel leakiness (Fig 9B–G). The degree
of vessel leakiness was associated with morphological changes in the
retina at the site of laser injury. A distorted retinal architecture was
apparent if a laser lesion was control-treated at the D28 time point,
as revealed by thickening of the retina, fibrosis and edematous
vacuoles; this was reduced upon treatment with RG7716 (Fig 9H–L).
Reduction in VEGF-A, ANG-2, and proinflammatory cytokines in aqueous
humor of antibody-treated animals
Levels of proangiogenic factors (VEGF-A, ANG-2) and proin-
flammatory cytokines interleukin-6 and interleukin-8 (IL-6 and
IL-8) in aqueous were compared in the treatment groups to the
isotype control. A first sample was taken 1 day after intravitreal
delivery of the antibody (D16), a time point of high inflammatory
response due to the intravitreal injection. The second sample was
taken close to the end of the experiment (D30). VEGF-A levels
only slightly increased from D16 to D30 in the IgG control (from
52.8  6.5 to 62.9  27.7 pg/ml). Anti-VEGF-A (ranibizumab) and
both treatments of RG7716 reduced aqueous VEGF-A levels
compared to isotype control being more significant at the early
time point rather than the late time point. Anti-ANG-2 administra-
tion did not affect VEGF-A levels (Fig 10A). Aqueous ANG-2 levels
increased in the isotype control from D16 to D30 (6.1  2.2 to
54.5  29.7 pg/ml), while all other treatments reduced ANG-2
levels at D30 (Fig 10B). IL-6 levels slightly increased (from
89.6  55.1 to 102.7  78.6 pg/ml) in the aqueous of IgG control
animals from D16 to D30. Reductions in IL-6 levels were achieved
with all antibodies at D30, but no early reduction in IL-6 levels
was evident 1 day after intravitreal injection (D16) (Fig 10C).
Table 1. Schematic presentation of amino acid changes of the Fc part
introduced into the human IgG1 framework of a CrossMAb.
Antibody and controls/
Fc mutations wt PG LALA AAA (IHH)
Wild-type anti-VEGF-A/ANG-2 y – –
Anti-VEGF-A/ANG-2-FcRc – y –
Anti-VEGF-A/ANG-2-FcRn – – y
RG7716 – y y
Wild-type anti-VEGF-A/ANG-2 shows naturally occurring configuration while
anti-VEGF-A/ANG-2 FcRc and anti-VEGF-A/ANG-2 FcRn have three amino
acid substitutions that disable FccR or FcRn binding, respectively. RG7716 is
carrying all amino acid substitutions disabling binding to both FcR classes.
Table 2. Positions of the exchanged amino acids are detailed below with the numbering according to Kabat and Wu (1991). In anti-VEGF-A/ANG-2-
FcRc−, the following substitution have been introduced: Leu234Ala, Leu235Ala, and Pro329Gly, and for anti-VEGF-A/ANG-2-FcRn−: Ile253Ala,
His310Ala, and His435Ala.
Short name Wt Position Mutation Affected Fc receptor
Anti-VEGF-A/ANG-2-FcRc (Schlothauer et al, 2013) PG P 329 G FccRI, II, III
LALA LL 234, 235 AA
Anti-VEGF-A/ANG-2-FcRn AAA I 253 A FcRn
H 310 A
H 435 A
Anti-VEGF-A/ANG-2-FcRn-FcRc RG7716 P 329 G FccRI, II, III, FcRn
LL 234, 235 AA
I 253 A
H 310 A
H 435 A
ANG-2, angiopoietin-2; VEGF-A, vascular endothelial growth factor-A.
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RG7716 at 90 lg reduced the IL-6 levels the most and achieved
significance. IL-8 levels in the aqueous were low, at an average of
3.2  1.4 pg/ml on D16, rising to 16.4  8.7 pg/ml on D30 in IgG
control animals. All antibodies, except anti-ANG-2, reduced IL-8
levels to below 3 pg/ml at D30 (Fig 10D). Again, as noted for IL-6,
RG7716 at 90 lg reduced IL-8 levels the most.
Discussion
Diabetic retinopathy and wAMD are the leading causes of severe
vision loss in middle-aged people and the elderly, respectively.
Anti-VEGF therapies effectively reduce the growth of neovessels
and the edema that is associated with these potentially blinding
conditions, and thus have become the standard of care. However,
despite the major medical advance, there is still an unmet patient
need.
The efficacy of intravitreal ranibizumab has been demonstrated
in patients with CNV secondary to wAMD in the pivotal phase III
studies MARINA and ANCHOR (Rosenfeld et al, 2006a,b; Chang
et al, 2007; Brown et al, 2009). The most obvious pharmacody-
namic effect seen with an anti-VEGF therapy is the reduction in reti-
nal edema. Using this measure, patients can be divided into one of
three categories: complete responders with no residual edema,
incomplete responders with partial edema resolution, and nonre-
sponders with no reduction in edema. Data from the pivotal trials
suggest that 5–10% of the wAMD population are nonresponders
and a large proportion of patients are incomplete responders. Data
from the HARBOR trial (Ho et al, 2014) and aflibercept pivotal
phase III trials VIEW 1 and VIEW 2 suggest that an efficacy ceiling
has been reached with anti-VEGF monotherapy in the wAMD popu-
lation, so novel therapeutic strategies are clearly needed. The next-
generation therapies will need to shift the overall distribution of the
patient response curve further to the responder side, and could
potentially increase the proportion of patients who experience
long-lasting improvements.
Using animal models of neovascular disease, we investigated
the concept of dual vs. mono-inhibition with the aim to identify
candidates that allow improving upon VEGF-A inhibitor monother-
apies in the clinic. Here we describe preclinical studies focused on
A B
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Figure 8. No platelet aggregation by RG7716 when antibody is complexed with VEGF-A and heparin in vitro and pharmacokinetic properties of RG7716 in
comparison with wild-type anti-VEGF-A/ANG-2.
A Bar graph demonstrating platelet aggregation induced by complexes of heparin, VEGF-A165, and anti-VEGF-A (IgG1) in vitro using washed human platelets.
Introduction of modification of the Fc region in RG7716 does not allow platelet aggregation to happen as compared to anti-VEGF-A as wild-type IgG1. All three
components are needed as heparin/anti-VEGF-A alone does not activate platelet aggregation. Error bars show SEM of three independent experiments and
**** denotes significance of heparin/VEGF-A/anti-VEGF-A comparing to IgG control using ANOVA (P < 0.0001) and Dunnett’s multiple t-test (****, P < 0.0001).
B Kinetic presentation of mean serum, vitreous, and aqueous humor concentrations after single intravitreal administration of 0.5 mg of RG7716 in cynomolgus
monkeys. Error bars indicate SEM with n = 6.
C Summary table of key experimental PK parameters of RG7716 and anti-VEGF-A/ANG-2-FccR (with intact FcRn binding).
Data information: AUC, area under the curve; Cmax, maximum concentration; t1/2, half-life; tmax, time to maximum serum concentration; tlast, time of collection of the last
of a series of blood samples; F, bioavailability; NA, not analyzed; PK, pharmacokinetic.
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Figure 9. Efficacy of RG7716 in a laser-induced CNV model using cynomolgus monkeys, comparing RG7716 to anti-VEGF-A (ranibizumab) and anti-ANG-2
(LC10), as well as an IgG control.
A Schematic representation of the experimental setup including treatment, sampling, and efficacy readouts.
B Inhibition of neovascularization measured in severity grades, change of severity from baseline is shown for each treatment; all treatment significantly reduced the
severity grade compared to IgG control. In addition, efficacy of RG7716 (150-kDa molecule at 90 lg/50 ll injected IVT) was significantly better at equal molar
concentration of binding sites than anti-VEGF-A (ranibizumab, 50-kDa molecule at 30 lg/50 ll injected IVT), anti-ANG-2, and the low dose of RG7716 (30 lg/50 µl
injected IVT). Error bars show SEM of n = 6 cynomolgus monkeys and nine spots per eye in the group; * denotes significance after one-sided ANOVA and Tukey’s multiple
t-test. IgG control is significantly different from anti-VEGF-A (****, P < 0.0001), anti-ANG-2 (***, P = 0.0003), RG7716, 30 lg (****, P < 0.0001), and RG7716, 90 lg (****,
P < 0.0001). Furthermore, RG7716, 90 lg is significantly different from RG7716, 30 lg (****, P < 0.0001), anti-ANG-2 (***, P = 0.0003), and anti-VEGF-A (***, P < 0.0004).
C–L (C–G) Representative figures of fluorescence fundus angiograms (H–L) of cross sections of a hematoxylin staining of a spot at the end of the experiment from eyes
treated with IgG control, anti-VEGF-A, anti-ANG-2, and RG7716 at 30 and 90 lg, respectively.
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Figure 10. Aqueous concentrations of VEGF-A, ANG-2, IL-6, and IL-8 samples 1 day after intravitreal antibody delivery (D16) and at the end of the experiment
(D30) in non-human primate laser-induced CNV.
A VEGF-A levels only slightly increased from D16 to D30 in the IgG control. At D16, levels of IgG control are significantly higher compared to anti-VEGF-A (++++,
P < 0.0001); RG7716, 30 lg (++++, P < 0.0001) and RG7716, 90 lg (++++, P < 0.0001). Anti-ANG-2 levels are comparable to IgG control and therefore significantly
different from anti-VEGF-A (++++, P < 0.0001); RG7716, 30 lg (++++, P < 0.0001) and RG7716, 90 lg (++++, P < 0.0001). At D30, the levels of VEGF-A are significantly
reduced in the RG7716, 90 lg group compared to IgG control (*, P = 0.0309). Anti-ANG-2 remains at levels comparable to IgG control and is therefore significantly
higher than RG7716, 30 lg (*, P = 0.0107), RG7716, 90 lg (**, P = 0.002), and anti-VEGF-A (*, P = 0.0162).
B ANG-2 levels increased from D16 to D30 in the IgG control. The same patterns, with a weaker total increase, were seen for the ANG-2 and both RG7716 treatment
groups. ANG-2 levels were significantly higher at D16 in the anti-VEGF-A-treated group compared to IgG control (++, P = 0.002), anti-ANG-2 (+++, P = 0.0004), RG7716,
30 lg (++++, P < 0.0001), and RG7716, 90 lg (++++, P < 0.0001). The reductions of treatments compared to IgG control at day 30 did not reach significance.
C IL-6 levels only very slightly increased from D16 to D30 in the IgG control, while for all other treatment groups there was a trend to reduced IL-6 levels at D30
compared to baseline with the high dose of RG7716 reaching significance, IgG control vs. RG7716, 90 lg (*, P = 0.023).
D IL-8 levels increased from D16 to D30 in the IgG control group. Compared to the IgG control, the levels of IL-8 were reduced in the anti-VEGF-A (*, P = 0.0262),
RG7716, 30 lg (*, P = 0.0188), and RG7716, 90 lg (*, P = 0.0107) treatments at D30.
Data information: Error bars show SEM, + and * denotes significance using one-sided ANOVA and Tukey’s multiple t-test with n = 6 cynomolgus monkeys. Data are
presented in linear scale; for the statistical analysis, data were transformed logarithmically to normalize distribution and allow parametric ANOVA testing. D16 (+) and
D30 (*) were analyzed independently. IL-6, interleukin-6; IL-8, interleukin-8; D, day.
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the dual targeting of ANG-2 and VEGF-A, key angiogenesis factors
that are upregulated in many human neovascular conditions.
Simultaneous inhibition of VEGF-A and ANG-2 was shown to be
superior to monotherapy in the reduction in neovascular area in
both early and late intervention studies in the mouse model of
spontaneous CNV. Early intervention in this model was used to
establish the principle that dual inhibition of VEGF-A and ANG-2
could reduce neovascularization and vessel leakiness. Follow-up
experiments using mice in which antibodies were delivered when
retinal lesions were already established demonstrated that
combined inhibition and anti-ANG-2 alone strongly reduced lesion
permeability. Late interference in the model did not reduce lesion
numbers as strongly compared to early intervention, as neovascu-
larization has taken place before antibody is given. Furthermore,
the efficacy of anti-ANG-2 alone was as strong as the bispecific
anti-VEGF-A/ANG-2 treatment at reducing lesion area in late inter-
ference. The results may highlight a more prominent role for
VEGF-A mediating neovascularization and ANG-2 mediating vessel
leakiness. At this stage, it is also not clear whether the small reduc-
tion in leaky lesion number in the late intervention model is due to
reduction in new lesions generated at the late time point or by
induction of lesion regression, a mechanism of action proposed for
the VEGF-A/PDGF-B dual targeting (Jo et al, 2006; Nishijima et al,
2007). However, permeability was strongly reduced by the anti-
VEGF-A/ANG-2 dual inhibition. The concept of strong control of
vascular permeability by anti-VEGF-A/ANG-2 is supported by the
OCT data, which showed a substantial reduction in retinal edema
following late intervening VEGF-A and ANG-2 dual inhibition. While
anti-ANG-2 reduced acute vessel leakiness as measured by FA,
reduction in retinal edema was stronger with anti-VEGF-A/ANG-2
as measured by OCT. This observation warrants further investiga-
tion. The resolution of edema will further assist the preservation of
normal retinal architecture, and is likely to lead to the findings of
reduced outer retinal cell loss and increased visual function, as
measured by ERG.
Experiments using an acute model of ocular inflammation, and
the CNV models, suggested that the mode of action upon dual
targeting of VEGF-A and ANG-2 may include an anti-inflammatory
component. VEGF-A and ANG-2 are both capable of enhancing
proinflammatory signals in endothelial cells. Intravital microscopy
was used by Fiedler and colleagues to demonstrate normal TNF-a-
induced leukocyte rolling in the vasculature of ANG-2-deficient
mice, but that rolling cells did not firmly adhere to activated
endothelium due to lower levels of adhesion molecules on the
surface of endothelial cells (Fiedler et al, 2006). Cellular experi-
ments showed that ANG-2 promotes adhesion by sensitizing
endothelial cells toward TNF-a and modulating the TNF-a-induced
expression of endothelial cell adhesion molecules. In addition, a
recent study reported that a mild (two- to threefold) overexpression
of VEGF-A in mice was sufficient to generate multiple pathological
responses in the eye, including increased oxidative stress and acti-
vation of the NLRP3 inflammasome, cataract formation, and non-
exudative AMD-like pathologies. IL-1 receptor-1-deficient mice did
not show this phenotype, demonstrating the importance of pro-
inflammatory mediators in enhancing signals that originate from
VEGF-A (Marneros, 2016).
In our studies, we observed that the bispecific antibody was
superior to either of the monotherapies in the reduction in
leukocyte infiltration in the LPS-induced inflammation model. Inter-
estingly, ANG-2 inhibition alone was only mildly inhibitory, which
was unexpected, since ANG-2 is often causally linked with
inflammatory responses. LPS is known to rapidly trigger ANG-2
release and inhibition of ANG-2 is sufficient to reduce sepsis mortal-
ity in different rodent models (Ziegler et al, 2013; Menden et al,
2015). In addition, in the model of sCNV, we report increased
numbers of IBA-1+ macrophages around lesions and, in the laser
CNV model, a reduction in aqueous levels of the cytokines IL-6 and
IL-8 upon VEGF-A blockade or dual VEGF-A/ANG-2 inhibition;
however, inhibition of ANG-2 alone had little effect. One likely
explanation is that there are redundant pathways activated during
major pathological insults, with the presumed biological aim of
ensuring a robust and rapid response. If true, combination therapy
approaches would certainly provide an advantage when responses
become deleterious, and, in this current study, the anti-angiogenic,
anti-edema, and anti-inflammatory advantages provided by dual
targeting provide compelling reasons to further pursue this thera-
peutic strategy.
There are two primary drug-targeting strategies for testing
whether the concept of dual inhibition of VEGF-A and the angiopoi-
etin pathway translates to human disease: use of an anti-VEGF-A
plus exposure to ANG-1 protein or inhibition of ANG-2 activity.
Various approaches have been used to convincingly demonstrate
that ANG-1 is important for maintaining vascular integrity and its
activity is overall anti-angiogenic. The transgenic expression of
ANG-1 resulted in leakage-resistant blood vessels (Thurston et al,
2000). Alternatively, adenoviral delivery (AAV2) of a recombinant
version of ANG-1, called COMP-ANG-1, demonstrated a protective
function of ANG-1 in models of choroidal neovascularization and
diabetic retinopathy (Cahoon et al, 2015; Lambert et al, 2016). An
oligomeric Tie-2 binding peptide called vasculotide showed protec-
tion against vascular leakage and mortality in a murine model of
polymicrobial abdominal sepsis (Kumpers et al, 2011); however,
the mode of action of this reagent is currently not fully understood
(Wu et al, 2015).
While these approaches provided strong evidence for the protec-
tive role of ANG-1 for normalizing vessel function, they also have
underscored, over the past two decades, the difficulty in producing
a version of ANG-1 protein that is amenable to therapeutic
approaches in the clinic.
Inhibition of ANG-2 was also shown in several preclinical oncol-
ogy, sepsis, and ophthalmology models, to reduce pathological
angiogenesis and vascular permeability (Saharinen et al, 2010;
Campochiaro, 2013; Ziegler et al, 2013). The precise mechanism of
action of ANG-2 appears to be complex, but can be partially
explained by competitive antagonism of ANG-2 with ANG-1 binding
to the Tie-2 receptor (Maisonpierre et al, 1997) and being an ampli-
fier of apoptotic signals in pericytes under stress (Cai et al, 2008;
Park et al, 2014).
Thus, we opted for inhibition of ANG-2 with classic therapeutic
reagents—in this case, neutralizing antibodies. A bispecific
CrossMAb antibody format offers the advantage of having to deliver
only a single molecule with a unique set of molecular properties by
intravitreal injection to neutralize two targets at once, in our case
VEGF-A and ANG-2. Co-formulation of antibodies or biologics using
the same paratope as in a CrossMAb is an alternative way to deliver
therapeutic drugs. In cases where one ligand is in large excess of the
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other, a co-formulation approach seems preferable to be able to
increase the dose of the reagent neutralizing the ligand in excess.
We consider the bispecific approach particularly suitable for soluble
ligands, like VEGF-A and ANG-2, which are detected at roughly
similar and low concentrations in fluids from the eye. VEGF-A levels
are reported to be in a range of 51.8–454 pg/ml in RVO (Noma et al,
2010; Koss et al, 2011, 2014). Slightly higher levels (792  203) are
reported for macular edema in aqueous fluids (Funatsu et al, 2003).
As reported here, these values for ANG-2 range from 139 pg/ml in
wAMD to 1,625 pg/ml in pDR (Fig 1). Therefore, both ligands are
available in comparative concentrations and both paratopes of the
CrossMAb have an equal probability of neutralizing their respective
ligands.
We designed RG7716 as a human IgG1-like CrossMAb. The
CrossMAb is a bispecific molecule design with one antigen-binding
site binding VEGF-A and the second one binding ANG-2. Point
mutations in the CH3 domain (“knobs-into-holes”) promote the
assembly of the two different heavy chains (Fig 6A). Exchange of
the CH1 and CL domains in the ANG-2-binding Fab promotes the
correct assembly of the two different light chains. This simple asym-
metric molecule design enables large-scale pharmaceutical produc-
tion in Chinese hamster ovary (CHO) cells (Schaefer et al, 2011).
The advantage of this process lies in the ability to use a well-
established IgG production work stream, including a standard CHO
fermentation.
RG7716 is capable of binding, neutralizing, and depleting both
human VEGF-A and ANG-2 simultaneously. Binding of the antibody
to ANG-1 was not detected, nor did it have inhibitory activity in an
ANG-1-driven endothelial cell survival assay using up to 100 lg/ml
of RG7716. This property was deemed extremely important, since
antibodies are delivered by intravitreal injection at high concentra-
tion (often milligrams/ml vitreous). Furthermore, while we detected
strongly elevated levels of ANG-2 in vitreous fluids of patients, we
also noted that ANG-1 is clearly present in the vitreous. Therefore,
all necessary components of the ANG-1/ANG-2/Tie-2 system are
present and selectivity is key to inhibition of ANG-2 to rebalance the
ANG-1/ANG-2 ratio in favor of ANG-1 signaling for it to promote
anti-angiogenesis, anti-vascular permeability, and vascular stability.
Since the strategy for achieving efficacy with RG7716 is based on
ligand neutralization, we rendered the antibody Fc region without
immune effector functions to optimize it for ophthalmological use.
VEGF-A accumulates in the extracellular matrix and, in the presence
of anti-VEGF-A, has been shown to activate platelets via the FccRIIa
receptor (Meyer et al, 2009) (Fig 8A). Activation of thrombocytes in
the choroid was reported by Julien et al (2014), who compared rani-
bizumab and Fc-containing aflibercept 7 days after intravitreal injec-
tion. Significantly, higher amounts of free hemoglobin and protein
complexes were found in the group treated with aflibercept, which
contains an immune effector function-competent Fc fragment. It is
anticipated that the Fc-engineered RG7716 has no similar potential
for platelet aggregation.
The other important interaction mediated by the Fc part of an
IgG1 is the interaction with recycling receptor FcRn. The systemic
half-life of IgG1 is kept high due to the interaction with FcRn,
which recycles IgG1 by preventing the antibody from being
degraded in the lysosome. We demonstrated that the systemic
half-life of RG7716 is considerably shorter than that of a normal
IgG in the cynomolgus monkey after intravitreal administration.
Importantly, the aqueous half-life of RG7716 was similar
compared to the same antibody with the FcRn binding site intact
(anti-VEGF-A/ANG-2-FccR in Fig 8B and C). In the non-human
primate CNV model, we also directly compared non-Fc region
modified IgG1s, a Fab fragment, and RG7716, and demonstrated
comparable concentrations in aqueous fluid; however, RG7716
was cleared faster from the systemic circulation than a wild-type
IgG1 competent for binding to FcRn (Appendix Fig S4A and B).
Anti-VEGF therapeutics have the potential to affect the systemic
cardiovasculature; therefore, rapid systemic clearance is a desir-
able feature for such an ophthalmic drug delivered by intravitreal
administration.
Our investigation also shows that the overall contribution of
FnRn-mediated clearance of antibodies from the eye is small. Kim
et al (2009) reported experiments that led the authors to conclude
that FcRn plays an important role in eliminating intravitreally
administered full-length IgGs across the blood–retinal barrier into
the systemic circulation. One experiment used chicken IgY, which
does not bind FcRn, and did not cross the blood–retinal barrier.
Intravitreal injection of hIgG1 (bevacizumab) resulted in less anti-
body crossing the blood–brain barrier in FcRn-deficient mice
compared to wild-type IgG. These experiments would argue that
elimination of FcRn binding may increase the vitreal half-life of
RG7716; however, our results are not in line with previous work
and show that this effect is small. Our experimental evidence
suggests a mainly passive transport mechanism of RG7716 out of
the eye, which would favor longer residence time for a larger mole-
cule due to an increase in hydrodynamic radius.
We chose the cynomolgus monkey CNV model of laser injury to
directly compare RG7716 to standard of care in clinical practice: the
anti-VEGF-A ranibizumab. The weak interaction of ranibizumab
with rodent VEGF-A did not allow comparisons in rodent models.
One advantage of the cynomolgus model is that antibody delivery is
by intravitreal injection, just as it is performed in the clinical setting.
We also targeted a later-timed intervention, 15 days after the initial
laser injury, to better reflect the clinical setting, where patients
present with established lesions. RG7716 showed a significantly
greater reduction in vessel permeability, as measured by fundus FA,
compared with monotherapy using equimolar concentrations.
However, a limitation of this laser model is that only low doses of
anti-angiogenics can be investigated, since administration of as little
as 30 lg of ranibizumab delivered by IVT were already efficacious.
The potential additional benefit of RG7716 in these respects may
finally only be demonstrable in clinical studies. Therefore, the
current experiment aims to establish the scientific basis of additional
benefit of RG7716 over ranibizumab monotherapy in the model of
laser-induced CNV in cynomolgus monkeys using a subclinical dose
delivered by intravitreal injection. These results support further
dose-escalation studies in humans.
In conclusion, the future of ophthalmological advances is
likely to be dependent upon the use of combination strategies to
improve patient outcomes, similar to oncology. Dual inhibition of
VEGF-A and ANG-2 showed increased efficacy compared to inhi-
bition of VEGF-A or ANG-2 alone, in several relevant preclinical
models of retinal neurovascular disease. RG7716 is a fully human
bispecific antibody capable of binding to all isoforms of VEGF-A
and, simultaneously, to ANG-2 without any binding to ANG-1
and features a modified Fc region, which results in lower
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systemic concentrations compared to wild-type IgG1 antibodies,
and a reduced potential for platelet activation. These efficacy and
pharmacokinetic data have been instrumental in supporting the
testing of RG7716 in humans for its potential in ophthalmological
indications. Appropriate safety studies have been conducted for
progression into single- and multiple-dose phase I studies in
patients with wAMD (NCT01941082). Currently, two phase II
proof-of-concept studies are underway to probe for improved
efficacy in humans in wAMD (NCT02484690) and DME
(NCT02699450).
Materials and Methods
RG7716 antibody production and Fc mutations
Cloning
The fusion genes comprising the antibody chains as described
below were generated by polymerase chain reaction (PCR) and/or
gene synthesis and assembled by known recombinant methods and
techniques. To disable FccR and FcRn binding, the mutations were
introduced in the human IgG framework as described in Tables 1
and 2 (T. Schlothauer et al, unpublished data). For the expression of
the described antibodies, expression plasmids for transient expres-
sion in HEK293-F cells (Invitrogen Corporation) were generated.
Expression
Bispecific antibodies were generated by transient transfection with
the four respective plasmids (encoding the heavy and the crossed
heavy chain, as well as the corresponding light and crossed light
chain) using the HEK293-F system (Invitrogen Corporation) accord-
ing to the manufacturer’s instructions.
Purification
Bispecific antibodies were purified from cell culture supernatants by
affinity chromatography using MabSelectSure-Sepharose (for non-
FcRn binding mutants) (GE Healthcare Europe GmbH) or kappa
Select-Agarose (for FcRn binding mutants) (GE Healthcare),
hydrophobic interaction chromatography using butyl-Sepharose
(GE Healthcare), and Superdex 200 size-exclusion (GE Healthcare)
chromatography.
The bispecific antibody-containing fractions were pooled,
concentrated to the required concentration using Vivaspin ultrafil-
tration devices (Sartorius Stedim Biotech S.A.), and stored at 80°C
in 20 mM histidine, 140 mM NaCl, pH 6.0.
Analytics
Purity and antibody integrity were analyzed after each purification
step by capillary electrophoresis–sodium dodecyl sulfate (CE-SDS)
using microfluidic Labchip technology (Caliper Life Science). The
aggregate content of antibody samples was analyzed by high-
performance size-exclusion chromatography (SEC) using a Superdex
200 analytical size-exclusion column (GE Healthcare) in 2× PBS
running buffer at 25°C.
Surrogates
To evaluate the efficacy of a combined anti-VEGF-A and anti-ANG-2
treatment in mouse models, we used B20-4.1 as a surrogate to
inhibit VEGF-A in the appropriate molecular format (Fab, IgG, or
CrossMAb) (Liang et al, 2006).
All FcRn, FccR, and simultaneous binding experiments were
measured on a BIAcore (GE Healthcare) system.
FcRn binding
Overlays were measured as described by Schlothauer et al (2013).
FccR binding overlay
Around 6,000 RU of the capturing system (1 lg/ml Penta-His anti-
body; Qiagen) were coupled on a CM5 chip (GE Healthcare Europe
GmbH) at pH 5.0 using an amine coupling kit. The sample and
system buffer was HEPES-buffered saline, pH 7.4. FccRI/IIa/IIIa-His
were captured by injecting a 100 nM solution for 60 seconds at a
flow of 5 ll/min. Binding was measured by injection of 100 nM of
CrossMAb for 180 s at a flow of 30 ll/min.
Assessment of independent VEGF-A and ANG-2 binding to the CrossMAb
Around 3,500 RU of the capturing system (10 lg/ml goat anti human
IgG) were coupled on a CM4 chip at pH 5.0 by using an amine
coupling kit (all reagents and buffers by GE Healthcare). The sample
and system buffer was PBS-T (10 mM PBS including 0.05% Tween-20)
pH 7.4. The bispecific antibody was captured by injecting a 10 nM
solution for 60 s at a flow of 5 ll/min. Independent binding of each
ligand to the bispecific antibody was assessed by order-of-addition
experiments (human VEGF-A concentration 200 nM, human ANG-2
concentration 100 nM). The surface was regenerated by 60 sec wash-
ing with a 3 mMMgCl2 solution at a flow rate of 30 ll/min.
Isothermal titration calorimetry
The affinities of the human (h)ANG-2 RBD-Fc fusion proteins,
hVEGF-A121 and hVEGF-A165, for RG7716 were measured using the
isothermal titration calorimeter iTC200 (GE Healthcare). hANG-2-
RBD-Fc, hANG-1-RBD-Fc, and RG7716 were all dialyzed against
15 mM HEPES, 200 mM NaCl, pH 7.4. Ligands were loaded into the
sample cell at a concentration of 4 lM and RG7716 applied via
syringe at a concentration of 60 lM by 12 injections of 3 ll follow-
ing a single injection of 1 ll to equilibrate the system. VEGF-A121,
VEGF-A165, and RG7716 were dialyzed against 1× PBS. VEGF-A121
or VEGF-A165 was loaded into the sample cell at concentrations of
4 lM or 2 lM, respectively. The antibody solution was applied via
syringe at a concentration of 40 lM via 17 injections of 2 ll follow-
ing a single injection of 0.5 ll to equilibrate the system. The experi-
mental titration curves were fitted to a one-site binding model using
Origin7 (OriginLab Corporation).
ANG-1 selectivity and TEER assay using endothelial cells
Stem cell-derived endothelial cells were grown on fibronectin-coated
flasks up to passage 3 and resuspended in assay medium (EBM-2 +
0.5% FCS) and transferred to fibronectin-coated 96-well plates using
12,000 cells/well (Patsch et al, 2015). After 24-h incubation,
120 ng/ml ANG-1 was added together with increasing concentra-
tions of antibody (up to 100 lg/ml) and incubated for 3 days. Cell
viability was measured with alamarBlue after 3-h incubation
measuring absorbance of alamarBlue at 570 nm, using 600 nm as
a reference wavelength.
For TEER measurements, fibronectin-coated 24-well transwell
inserts were seeded with 1 × 105 primary human endothelial cells in
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100 ll growth medium (EGMTM-2). After 2 days, the medium was
changed to endothelial assay medium (EBMTM-2 supplemented with
SingleQuots kit excluded VEGF-A, only with 0.5% FCS) and
cultured for 2 more days before the transwells were placed into the
CellZscope (NanoAnalytics). TEER was then measured continu-
ously in a CO2 incubator at 37°C. After 8 h, cells were treated with
VEGF-A (basal) and ANG-1 or anti-ANG-2 (apical and basal),
respectively, and continued for TEER measurements. ANG-2 levels
of primary endothelial supernatants were measured with the DUO-
Set human ANG-2 ELISA from R&D according to the instruction
leaflet. Supernatants have been diluted in reagent diluent from R&D
and TMB substrate used for detection.
Washed platelets: preparation and aggregation
Human blood was collected in 85 mM trisodium citrate, 67 mM
citric acid, glucose 111.5 mM, pH 4.5, in final concentration
0.02 U/ml apyrase and 0.5 lM prostacyclin (PGI2) was added as
an anticoagulant. Platelet-rich plasma (PRP) was prepared and
platelets were resuspended in 20 mM NaCl, 13 mM trisodium
citrate, 30 mM dextrose, pH 7.0 + 1 lM PGI2 + 0.02 U/ml apyrase
before being twice pelleted (760 g at room temperature) and was
resuspended in buffer as before. After the third centrifugation, the
pellet was resuspended in ETS buffer (37°C) (154 mM NaCl,
10 mM Tris–HCl, 1 mM EDTA, pH 7.4) + 1 lM PGI2 + 0.02 U/ml
apyrase. After a last centrifugation (760 g at room temperature),
the pellet was finally resuspended in Tyrode’s buffer (37°C)
(133 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, NaH2PO4 0.36 mM,
10 mM HEPES, 5 mM glucose, 2 mM CaCl2, 1 mM MgCl2, BSA
0.2%; pH 7.4) + 0.02 U/ml apyrase. After resting for an hour at 37°C,
platelet concentration was adjusted to 2 × 108 platelets/ml. A
total of 300 ll of washed platelets was added to each well of a
32-channel aggregation plate (custom product, equivalent to a
32-channel aggregometer), stirred for 3 min, and primed in the
presence of 2.5–5 mM of adenosine diphosphate. After 20 s, 20 ll
of antibody/VEGF-A/heparin mixtures was added and, another
3–5 min later, 20 ll of fibrinogen was added. Readout was
percentage aggregation.
Measurement of ANG-1 and ANG-2 levels in vitreous fluids from
patients with retinal disease
Vitreous samples of patients with wAMD, diabetic retinopathy, reti-
nal vein occlusion, and macular hole were collected by Dr. M. Koss,
University of Heidelberg (Koss et al, 2011). Collection of samples
was performed after local full ethics committee approval (57/08) in
accordance with the European Guidelines for Good Clinical Practice
and the Declaration of Helsinki. Informed consent was obtained
from each patient before the start of therapy. Samples were stored
at 70°C and transferred to Roche for the analysis of ANG-1 and
ANG-2 using a multiplex Luminex kit produced in-house using the
following reagents: anti-ANG-1 capture (R&D, MAB9231) and anti-
ANG-1 detection (Novus Biologicals, NB110-85464), anti-ANG-2
capture (R&D, MAB098) and anti-ANG-2 detection (R&D,
BAM0981). Capture antibodies were coupled to Luminex beads
using the Bio-Plex Amine Coupling Kit (Bio-Rad 171406001).
Vitreous samples diluted one-third were incubated with capture
antibody bead for 2 h. After washing the beads, biotinylated
detector antibodies were added and incubated with the beads for
1 h. Streptavidin-conjugated fluorescent protein, R-phycoerythrin
(BD, 554061), was then added and incubated for 30 min. After
washing, the beads were analyzed using a Luminex 100 detection
system.
Spontaneous CNV model in JR5558 mice
All procedures on mice were ethically reviewed and approved
according to the British Home Office Animals Scientific Procedures
Act 1986 and were performed in accordance with European Direc-
tive 86/609/EEC, the Roche Ethics Committee on Animal Welfare
(ECAW), and the statement for the use of animals in ophthalmic
and vision research approved by the Association for Research in
Vision. Fundus FA was performed on unanesthetized mice using a
Digital Kowa Genesis Fundus camera for small animals (Kowa
OptiMed, Tokyo, Japan). Imaging was initiated once the pupils were
fully dilated (~2 mm diameter). Sodium fluorescein (NaF) (2%) was
injected IP (13.5 ll/g body weight). Early-phase angiograms were
captured 90 s after injection, followed by late-phase angiograms at
5 min. Multiple images were captured at each time point covering
the central retinas (~75° field of view). Areas of fluorescein leakage
adjacent to angiogenic lesions were manually selected and number
of, area, and brightness in early- and late-phase angiographies
measured (ImageJ, Wayne S. Rasband, NIH, Bethesda, Maryland,
USA).
Optical coherence tomography was performed using the
Heidelberg Spectralis with a +25 diopter achromatic lens attached to
the front of the device. A custom-made PMMA contact lens (Cantor
& Nissel Ltd, UK) was used to avoid dehydration of the cornea of
anaesthetized mice. OCT scans were obtained from a 1.5-mm2
region at 10-lm intervals of the central nasal retina simultaneously
with FA (see above). The data were analyzed using a Canny edge-
based segmentation algorithm, which delineated the outer segment
and retinal pigment epithelium, and the volume separating the two
was calculated (MATLAB). Data sets collected from the same region
and eye of the same animal at baseline, after 1 week, and at the end
of the study were geometrically aligned and change in subretinal
volume quantified.
Standard full-field scotopic and photopic large-field ERGs were
recorded from dark-adapted (12 h) and light-adapted mice (Micron
III with ERG adapter, Phoenix Research Laboratories). Scotopic
recordings were performed under dim red light. Series of 5-ms
single-flash recordings were obtained at increasing light intensities
from 2.5 to 3.0 log cds/m2. Twenty responses per intensity were
averaged with an interstimulus interval of 20 s. A- and B-wave
amplitudes and implicit times were evaluated (Labscribe, iWork
System Inc.).
Ocular tissues were collected 24 h after the last FA. Eyes were
removed and snap-frozen in isopentane on dry ice. From frozen
eyes, vitreous, retina, and retinal pigment epithelium (RPE)/choroid
samples were isolated. Alternatively, eyes were enucleated and fixed
overnight in 4% paraformaldehyde for immunohistochemistry of
whole-mounts of retinae and of the RPE/choroid complex (eyecup).
Alternatively, eyeballs were cryoprotected in 30% sucrose and
snap-frozen in Optimal Cutting Compound 4585 (OCT, Tissue-Tek;
Miles, Elkhart, IN), and cryostat sections (10 lm) were thaw-
mounted onto charged slides. Retinal sections were blocked for 1 h
in 5% normal donkey serum in 0.1 M PBS, pH 7.4 with 0.3% Triton
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X-100 and incubated for 2 h at room temperature with primary anti-
bodies. After washing, slides were exposed for 1 h to fluorescently
conjugated appropriate secondary antibodies. Nuclei were subse-
quently stained with 40,6-diamidino-2-phenylindole (DAPI). Slides
were washed for 3 × 5 min in 0.1 M PBS and finally cover-slipped
using Vectashield (Vector Laboratories). TUNEL analysis was
performed as recommended by the supplier, Promega DeadEnd
Fluorometric TUNEL System. TUNEL-positive cells were counted in
whole-mount preparations of neural retinas. Whole-mount retinas
and eyecups were imaged using a laser scanning confocal
microscope (Zeiss LSM 710; Carl Zeiss) at 8 bit/channel and
1,024 × 1,024 pixels. Sections were viewed and images captured on
an epifluorescence bright-field microscope (Olympus BX50F4,
Olympus), where data were captured as 36-bit color images at
3,840 × 3,072 pixel resolution using a Retiga SRV camera
(QImaging).
Single-dose pharmacokinetic study, intravitreal
dose administration
A single-dose pharmacokinetic study was conducted by Covance
Laboratories Inc. (Madison, Wisconsin, USA). All procedures in the
study were carried out in compliance with the Animal Welfare Act
Regulations (9 CFR 3). Six male cynomolgus monkeys received a
single-dose intravitreal injection (50 ll with 1.5 mg/eye of
RG7716). Blood was collected into serum separator tubes at indi-
cated times post-dose. Serial aqueous humor samples were
collected at 72, 168, and 336 h post-dose. Serum, aqueous, and
vitreous humor samples were analyzed for RG7716 concentration
with an ELISA that uses anti-idiotypic antibodies (Stubenrauch
et al, 2013).
Laser-induced CNV in cynomolgus monkeys
Experimentation on non-human primates (Macaca fascicularis)
was performed in accordance with the Statement for the Use of
Animals in Ophthalmic and Vision Research approved by the
Association for Research in Vision and Ophthalmology. The guide-
lines of the Animal Ethics Committee of the Singhealth Singapore
Association for Assessment and Accreditation of Laboratory
Animal Care were also satisfied. In this study, five groups of six
female cynomolgus monkeys at 3–5 kg body weight (n = 30) were
used. CNV was induced by laser photocoagulation on D0 in both
eyes of 30 cynomolgus monkeys using a 532-nm laser (PurePoint
532 nm Green Laser; Alcon) attached to a slit-lamp delivery
system and a hand-held contact lens. Nine lesions were symmetri-
cally placed in the macula of each eye by a masked retinal
specialist. The parameters used were spot size (50 lm), duration
(0.1 s), and 500 mW–1 W. The distance from each laser spot to
the central fovea was maintained at 0.5–1 disk diameter size.
Intravitreal injections of 50 ll antibody solution per eye were
performed on both eyes on D15. Change in CNV grade was deter-
mined by comparing FA on D28 vs. D14. FA was performed using
a commercial camera and imaging system (TRC-50DX Fundus
camera; Topcon) at 14 and 28 days after laser photocoagulation.
Photographs were captured with the fundus camera lens after
intravitreal injection of 0.1 ml/kg of body weight of 10% fluores-
cein sodium. A masked retina specialist not involved in laser
photocoagulation or angiography evaluated the FA at a single
sitting.
On D30, the animals were sacrificed and the upper body was
perfused with half-strength Karnovsky’s fixative. The eyes were
removed, postfixed for 2–3 days in half-strength Karnovsky’s
fixative. Strips of tissue containing one or two lesion sites were
embedded in plastic. Sections 2-lm thick were taken at 30-lm steps
through the middle of each lesion and stained with toluidine blue.
Aqueous humor was collected from all eyes on D16 (1 day after
intravitreal injection of antibody) and D30. Cytokine analysis of
aqueous was performed by multiplex ELISA system measuring IL-6,
IL-8, VEGF-A, and ANG-2. Blood was taken from a femoral or
saphenous vein at indicated days. All samples were maintained at
room temperature and allowed to clot, then chilled and centrifuged
within 1 h of blood collection, and stored at 80°C.
Expanded View for this article is available online.
The paper explained
Problem
Age-related macular degeneration (AMD) is a major cause of vision
loss in the elderly population. Severe vision loss is seen in the wet
form of the disease. Critical initiator of disease are neovessels that
grow from choroidal vessels to underneath and into the retina. These
are immature in phenotype and are therefore leaky, leading to distor-
tion of the tissue architecture, which impacts the functionality of the
retina. Neutralization of VEGF-A, a major driver of vessel neoangiogen-
esis and leakiness, by biological reagents is currently the standard of
care to treat wet AMD. However, medical need remains as not all
patients gain visual acuity. It is therefore import to enhance the effi-
cacy of VEGF-A-neutralizing reagents.
Results
Angiopoietin-2 (ANG-2) is another important growth factor involved in
neoangiogenesis and vessel leakiness. We tested whether dual inhibi-
tion of VEGF-A and ANG-2 is more efficacious compared to inhibition
of VEGF-A alone in animal models of choroidal neovascularization. In
a mouse model of spontaneous choroidal neovascularization, we saw
dual inhibition reduces vessel leakiness and the total number of
lesions. As a consequence, retinal functionality was protected as
revealed by electroretinogram and the number of apoptotic cells in
the retina was reduced. In a non-human primate model of laser-
induced choroidal neovascularization, we confirmed that dual inhibi-
tion of VEGF-A and ANG-2 is more efficacious in reducing the leaki-
ness of lesions after intravitreal delivery of neutralizing antibodies. For
the non-human primate model, we used RG7716, which is a CrossMAb
specifically designed for the application in ophthalmology. This anti-
body potently binds and neutralized VEGF-A with one antigen-binding
arm and very selective anti-ANG-2 on the other. Its Fc domain is
disabled for interaction with FccR and FcRn reducing the potential for
platelet activation and reducing the systemic half-life of the antibody.
Impact
This study demonstrated that dual inhibition of VEGF-A and ANG-2 is
more efficacious in preclinical models of choroidal neovascularization
compared to inhibition of VEGF-A alone. We therefore generated a
human CrossMAb RG7716, which has been tested in single- and
multiple-dose phase I studies in patients with wet AMD
(NCT01941082), and two phase II studies to test the concept of
improved efficacy in proof of concept studies in humans are ongoing
in wAMD (NCT02484690) and DME (NCT02699450).
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